Cyclo Therapeutics, Inc. financial data

Symbol
CYTH, CYTHW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
6714 Nw 16 Th Street, Suite B, Gainesville, Florida
State of incorporation
Nevada
Fiscal year end
December 31
Former names
CTD HOLDINGS INC (to 9/30/2019), CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC (to 3/30/2000)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 104 % -52.3%
Quick Ratio 3.4 % -57.2%
Return On Equity -2.74K % -506%
Return On Assets -253 % -2.46%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.7M shares +172%
Common Stock, Shares, Outstanding 28.6M shares +185%
Entity Public Float 17.2M USD +17.2%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 28.6M shares +160%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.6M USD +20.5%
Costs and Expenses 21.2M USD +12.3%
Operating Income (Loss) -20.2M USD -14%
Nonoperating Income (Expense) 771K USD +1655217%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.4M USD -9.65%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -19.4M USD -9.65%
Earnings Per Share, Basic -0.92 USD/shares +53.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3M USD +227%
Accounts Receivable, after Allowance for Credit Loss, Current 71.3K USD -45.6%
Inventory, Net 243K USD -0.81%
Assets, Current 6.57M USD +64.5%
Property, Plant and Equipment, Net 24.3K USD -51.7%
Operating Lease, Right-of-Use Asset 569K USD +967%
Assets 7.16M USD +74.8%
Accounts Payable, Current 3.67M USD
Liabilities, Current 6.54M USD +45.3%
Operating Lease, Liability, Noncurrent 17.5K USD -52.1%
Retained Earnings (Accumulated Deficit) -88.2M USD -28.2%
Stockholders' Equity Attributable to Parent 610K USD
Liabilities and Equity 7.16M USD +74.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.18M USD -41.5%
Net Cash Provided by (Used in) Financing Activities -69.3K USD -102%
Net Cash Provided by (Used in) Investing Activities -2.42K USD -106%
Common Stock, Shares Authorized 250M shares +400%
Common Stock, Shares, Issued 28.6M shares +185%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.25M USD -895%
Interest Paid, Excluding Capitalized Interest, Operating Activities 756 USD -56.3%
Deferred Tax Assets, Valuation Allowance 24.8M USD +7.17%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 1.03M USD
Depreciation 19.3K USD -1.05%
Payments to Acquire Property, Plant, and Equipment 2.42K USD -84%
Lessee, Operating Lease, Liability, to be Paid 1.04M USD
Property, Plant and Equipment, Gross 159K USD +1.54%
Operating Lease, Liability, Current 648K USD +3716%
Lessee, Operating Lease, Liability, to be Paid, Year Two 21.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.02M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure -50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.9K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.8K USD
Deferred Tax Assets, Operating Loss Carryforwards 12.6M USD +17.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 6.95M USD
Additional Paid in Capital 88.8M USD +29.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.18K USD -54.8%
Deferred Tax Assets, Net of Valuation Allowance 230K USD +5650%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%